Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taltz vs Enbrel and Placebo in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2)
NCT01597245Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2012
- Primary completion
- Mar 2014
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 3 trial of ixekizumab in plaque psoriasis, sponsored by Eli Lilly and Company. Started May 2012; status: completed.
02
Drugs
ixekizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01597245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01597245.